Investment analysts at Needham & Company LLC assumed coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) in a research note issued to investors on Friday,Benzinga reports. The brokerage set a “buy” rating and a $56.00 price target on the stock. Needham & Company LLC’s price target would indicate a potential upside of 74.45% from the company’s current price.
A number of other analysts have also weighed in on FTH. Citigroup started coverage on Sensei Biotherapeutics in a research note on Friday, May 22nd. They issued a “buy” rating and a $55.00 target price for the company. Raymond James Financial assumed coverage on shares of Sensei Biotherapeutics in a report on Friday, July 31st. They set an “outperform” rating and a $56.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Sensei Biotherapeutics in a research report on Thursday, June 4th. BTIG Research reaffirmed a “buy” rating and issued a $55.00 target price on shares of Sensei Biotherapeutics in a research note on Thursday, July 16th. Finally, Weiss Ratings initiated coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Sensei Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $55.00.
Read Our Latest Research Report on Sensei Biotherapeutics
Sensei Biotherapeutics Stock Performance
Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($5.04) by $2.20. On average, research analysts anticipate that Sensei Biotherapeutics will post -13.18 earnings per share for the current year.
Insiders Place Their Bets
In other Sensei Biotherapeutics news, CFO Brian C. Stephenson bought 5,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were bought at an average cost of $23.50 per share, for a total transaction of $117,500.00. Following the transaction, the chief financial officer owned 46,688 shares in the company, valued at approximately $1,097,168. This trade represents a 11.99% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Anand Kiran Parikh purchased 2,806 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The shares were acquired at an average cost of $19.76 per share, with a total value of $55,446.56. Following the completion of the purchase, the chief executive officer owned 764,234 shares of the company’s stock, valued at $15,101,263.84. The trade was a 0.37% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders bought 49,494 shares of company stock valued at $1,188,822. 7.00% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in FTH. Vivo Capital LLC bought a new stake in Sensei Biotherapeutics in the first quarter valued at about $22,758,000. Alyeska Investment Group L.P. bought a new position in Sensei Biotherapeutics during the second quarter worth about $3,610,000. Stempoint Capital LP bought a new position in Sensei Biotherapeutics during the first quarter worth about $4,188,000. Bank of America Corp DE grew its position in shares of Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after buying an additional 32,719 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after buying an additional 20,525 shares during the period. 10.50% of the stock is currently owned by institutional investors.
About Sensei Biotherapeutics
Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.
The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.
Featured Stories
- Five stocks we like better than Sensei Biotherapeutics
- Coherent Stock Is Cooling Off Just as Its AI Thermal Opportunity Heats Up
- Moderna’s 177% Surge Has Investors Asking What Comes Next
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
